Direct Cpmpetitor Analysis - PFE VS Other Big Pharma
PFE is damn cheap at these levels ( 8.6 times earnings). All these pharma have a revenue growth of +/- 1 - 2%. Pfizer needs a better management, PR and perhaps a new CEO with a vision. They should increase dividend instead of buying back shares which is not helping the stock. Secondly, they should focus of buying smaller companies with similar profile instead of elephants like AZN .